On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
On-demand therapy is effective for maintaining symptoms control in nonerosive gastroesophageal reflux disease (GERD). Our aim was to assess the clinical effectiveness of on-demand therapy with a proton pump inhibitor (PPI) in mild GERD (nonerosive and low-grade esophagitis), its impact on health-related quality of life (HRQoL), and the degree of patient satisfaction. Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day. The healed patients started on-demand therapy. We evaluated symptoms (clinical questionnaire), HRQoL (SF-36 questionnaire), and patient satisfaction (visual analogue scale). Of the 55 patients included, 51 started on-demand therapy for 6 months. Symptom control (heartburn <twice a week) was achieved in over 85% of the patients. The mean (SD) amount of PPI used was 0.3 (0.19) tablet/day. The patient satisfaction score at the end of the acute phase was 98 (range, 0-100) and remained high (90; range, 10-100) and stable during on-demand therapy. Short-term treatment normalized the HRQoL scores, which were subsequently maintained during on-demand therapy. On-demand therapy is useful for the clinical management of patients with mild GERD, allowing adequate symptoms control, limiting PPI consumption, and affording important patient satisfaction with normalization of HRQoL.
Gastroenterology Unit, La Fe University Hospital, Valencia, Spain.
Julio
J
Ponce
Lidia
L
Argüello
Guillermo
G
Bastida
Marta
M
Ponce
Vicente
V
Ortiz
Vicente
V
Garrigues
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D004941:Esophagitis / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D064750:Rabeprazole; D055502:Secondary Prevention; D012720:Severity of Illness Index; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D009853:Omeprazole